Celcuity (NASDAQ:CELC) Sets New 52-Week High - Here's What Happened
Celcuity (NASDAQ:CELC) reached a new 52-week high at $102.15. Analysts have mixed ratings, with a consensus target price of $97.00. The company reported better-than-expected earnings, with EPS of ($0.92) beating estimates. Insider trading saw Director Richard E. Buller sell shares, while hedge funds increased stakes. Celcuity focuses on targeted therapies for solid tumors. The stock is owned 63.33% by institutional investors.
Shares of Celcuity, Inc. (NASDAQ:CELC - Get Free Report) reached a new 52-week high during trading on Monday . The company traded as high as $102.15 and last traded at $101.8880, with a volume of 248158 shares. The stock had previously closed at $97.50.
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on the company. HC Wainwright reiterated a "neutral" rating and issued a $94.00 target price (up previously from $77.00) on shares of Celcuity in a report on Monday, November 17th. Guggenheim started coverage on Celcuity in a report on Monday, September 22nd. They issued a "buy" rating on the stock. Needham & Company LLC set a $95.00 price objective on Celcuity in a research note on Monday, October 20th. Leerink Partners increased their target price on shares of Celcuity from $28.00 to $60.00 and gave the stock an "outperform" rating in a research report on Monday, July 28th. Finally, Stifel Nicolaus raised their price target on shares of Celcuity from $68.00 to $115.00 and gave the company a "buy" rating in a report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $97.00.
Get Our Latest Research Report on CELC
Celcuity Stock Performance
The stock has a 50 day simple moving average of $65.17 and a 200 day simple moving average of $40.06. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 2.74. The company has a market cap of $4.68 billion, a price-to-earnings ratio of -27.56 and a beta of 0.72.
Celcuity (NASDAQ:CELC - Get Free Report) last announced its earnings results on Wednesday, November 12th. The company reported ($0.92) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.13. As a group, analysts predict that Celcuity, Inc. will post -2.62 EPS for the current year.
Insider Buying and Selling at Celcuity
In related news, Director Richard E. Buller sold 3,900 shares of the firm's stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $96.73, for a total transaction of $377,247.00. Following the completion of the sale, the director directly owned 7,260 shares of the company's stock, valued at approximately $702,259.80. This trade represents a 34.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 15.77% of the company's stock.
Hedge Funds Weigh In On Celcuity
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Harvest Investment Services LLC acquired a new stake in shares of Celcuity during the third quarter valued at about $1,427,000. Voloridge Investment Management LLC acquired a new stake in Celcuity during the 3rd quarter valued at approximately $9,439,000. Verition Fund Management LLC purchased a new stake in Celcuity during the 3rd quarter worth approximately $4,012,000. Scientech Research LLC acquired a new position in shares of Celcuity in the 3rd quarter valued at approximately $777,000. Finally, Qube Research & Technologies Ltd purchased a new position in shares of Celcuity during the 3rd quarter valued at approximately $329,000. 63.33% of the stock is owned by hedge funds and other institutional investors.
Celcuity Company Profile
(Get Free Report)Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
See Also
- Five stocks we like better than Celcuity
- 3 Dividend Kings To Consider
- Hims, Block, and NRG Just Launched Huge Stock Buybacks
- 3 Best Fintech Stocks for a Portfolio Boost
- Retail Earnings Roundup: Walmart Scores, Target Slumps in Q3
- When to Sell a Stock for Profit or Loss
- JPMorgan and Goldman Upgrade MP Materials Amid Defense-Driven Demand Outlook
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Celcuity Right Now?
Before you consider Celcuity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.
While Celcuity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
